Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Gower Publishing

- PMLiVE

Regeneron scores first FDA approval for Ebola antibody treatment

Treatment cut mortality rate in study based in the Democratic Republic of Congo

- PMLiVE

Biopharma industry encouraged by EMA’s COVID-19 transparency measures

IFPMA and EFPIA welcome new transparency measures for potential treatments and vaccines

- PMLiVE

Roche to collaborate with Dyno on gene therapies for CNS/liver diseases

Dyno will use its CapsidMap platform to develop novel AAV vectors for improved gene therapies

- PMLiVE

Looking after the mental wellbeing of the Porterhouse family

At Porterhouse Medical Group, as a busy insight-led healthcare communications agency group, we recognise the importance of mental health and that mental health issues are a normal part of life...

Porterhouse Medical Group

OLED Medical Technology Saving Patient’s Sight During COVID-19 Pandemic

North East MedTech company secures investment agreement with Japanese tech giant

Onyx Health

- PMLiVE

Celltrion launches phase 3 trial of COVID-19 mAb

Investigational monoclonal antibody will be tested as a preventative treatment

- PMLiVE

Adapting to a pandemic: small changes can make a big difference

By Peter Impey

- PMLiVE

Eli Lilly’s COVID-19 antibody trial paused due to safety issue

Company has voluntarily paused study amid safety review

- PMLiVE

Shionogi’s novel antibiotic trial data published in The Lancet

Data from APEKS-NP and CREDIBLE-CR studies published

- PMLiVE

Relief Therapeutics’ COVID-19 drug shows positive results ahead of trial readout

Patients treated in intensive care met survival threshold in open-label study

- PMLiVE

Mallinckrodt files for bankruptcy protection in the US

Bankruptcy filing will reduce debts related to legal liabilities

- PMLiVE

J&J halts COVID-19 vaccine study after unexplained participant illness

Company convened data and safety monitoring board to review event

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links